Prima BioMed Ltd Company Profile (NASDAQ:PBMD)

About Prima BioMed Ltd

Prima BioMed Ltd logoPrima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PBMD
  • CUSIP:
Key Metrics:
  • Previous Close: $2.48
  • 50 Day Moving Average: $2.50
  • 200 Day Moving Average: $1.26
  • 52-Week Range: $20,616,000.00 - $0.51
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.86
  • P/E Growth: 0.00
  • Market Cap: $50.92M
  • Outstanding Shares: 20,616,000
  • Beta: 1.83
Debt:
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 14.75%
  • Quick Ratio: 14.75%
Additional Links:
Companies Related to Prima BioMed Ltd:

Analyst Ratings

Consensus Ratings for Prima BioMed Ltd (NASDAQ:PBMD) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.63 (168.22% upside)

Analysts' Ratings History for Prima BioMed Ltd (NASDAQ:PBMD)
Show:
DateFirmActionRatingPrice TargetDetails
1/24/2017FBR & CoReiterated RatingBuy$6.00View Rating Details
1/7/2017HC WainwrightReiterated RatingBuy$7.50View Rating Details
12/30/2016Maxim GroupReiterated RatingBuy$16.67 -> $7.00View Rating Details
8/26/2016Roth CapitalReiterated RatingBuy$6.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Prima BioMed Ltd (NASDAQ:PBMD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Prima BioMed Ltd (NASDAQ:PBMD)
Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS

Dividends

Dividend History for Prima BioMed Ltd (NASDAQ:PBMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prima BioMed Ltd (NASDAQ:PBMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Prima BioMed Ltd (NASDAQ:PBMD)
DateHeadline
investopedia.com logoPrima BioMed Bets Big on Cancer Drug IMP321 (PBMD) (NASDAQ:PBMD)
www.investopedia.com - February 17 at 4:48 PM
investopedia.com logoPrima BioMed Bets Big on Cancer Drug IMP321 (NASDAQ:PBMD)
www.investopedia.com - February 17 at 4:48 PM
News IconInvestor Study: Looking at the Levels for Prima Biomed Ltd. (PBMD) - Baxter Review (NASDAQ:PBMD)
baxternewsreview.com - February 16 at 11:43 PM
News IconPrima Biоmed: AIPAC Phase Ilb Starts Randоmized Cоmpоnent (NASDAQ:PBMD)
newscame.com - February 16 at 6:42 PM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Prima BioMed Ltd (NASDAQ:PBMD) - Aiken Advocate (NASDAQ:PBMD)
aikenadvocate.com - February 13 at 9:38 PM
finance.yahoo.com logoPrima BioMed Receives ~A$860,000 Tax Credit Payment From French Government (NASDAQ:PBMD)
finance.yahoo.com - February 13 at 12:02 AM
wsj.com logo[$$] Temasek, Others Plan to Sell Stake in Indonesian Retailer (NASDAQ:PBMD)
www.wsj.com - February 2 at 1:47 AM
News IconMA Levels in Review for Prima Biomed Ltd. (PBMD) - Sherwood Daily (NASDAQ:PBMD)
sherwooddaily.com - January 24 at 8:47 AM
News IconSell-side Consensus Sees Prima BioMed Ltd (NASDAQ:PBMD) Going Where Near-Term? - Aiken Advocate (NASDAQ:PBMD)
aikenadvocate.com - January 24 at 8:47 AM
finance.yahoo.com logoPrima Biomed Initiates Randomized Study for Breast Cancer (NASDAQ:PBMD)
finance.yahoo.com - January 23 at 9:37 AM
finance.yahoo.com logoPrima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference (NASDAQ:PBMD)
finance.yahoo.com - January 22 at 11:54 PM
News IconDiverse Stocks in Expert's Opinion: CSX Corporation (NASDAQ:CSX), Prima Biomed Ltd. (NASDAQ:PBMD) - Street Wise Report (press release) (blog) (NASDAQ:PBMD)
streetwisereport.com - January 21 at 8:01 AM
News IconAmplified Volatility Spotted in Shares of Prima Biomed Ltd. (NASDAQ:PBMD) - Wall Street Beacon (NASDAQ:PBMD)
wsbeacon.com - January 21 at 8:01 AM
finance.yahoo.com logoPrima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer (NASDAQ:PBMD)
finance.yahoo.com - January 19 at 11:49 PM
News IconTrend Strength Monitor on Shares of Prima Biomed Ltd. (PBMD) - Sherwood Daily (NASDAQ:PBMD)
sherwooddaily.com - January 19 at 5:47 AM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Prima Biomed Ltd. (NASDAQ:PBMD) - Wall Street Beacon (NASDAQ:PBMD)
wsbeacon.com - January 19 at 5:47 AM
streetinsider.com logoPrima BioMed (PBMD) Regains NASDAQ Compliance - StreetInsider.com (NASDAQ:PBMD)
www.streetinsider.com - January 18 at 8:45 AM
News IconEquity Insight: Indicator Review for Prima Biomed Ltd. (PBMD) - Sherwood Daily (NASDAQ:PBMD)
sherwooddaily.com - January 17 at 7:29 PM
finance.yahoo.com logoPrima BioMed Commences Recruitment for Second Cohort of Melanoma Trial (NASDAQ:PBMD)
finance.yahoo.com - January 11 at 7:46 PM
News IconEye Catching Active Stocks: Sony Corporation (NYSE:SNE), Prima ... - Street Wise Report (press release) (blog) (NASDAQ:PBMD)
streetwisereport.com - January 7 at 11:23 PM
News IconBlackBerry Limited (NASDAQ:BBRY)- Active Momentum Stocks in New Buzz: Prima Biomed (NASDAQ:PBMD) - Street Wise Report (press release) (blog) (NASDAQ:PBMD)
streetwisereport.com - January 7 at 5:55 AM
rttnews.com logoWall Street Set For Mixed Opening (NASDAQ:PBMD)
www.rttnews.com - January 6 at 4:53 AM
News IconPrima BioMed joins with Japanese firm - Finance News Network (NASDAQ:PBMD)
www.finnewsnetwork.com.au - January 5 at 11:52 PM
News IconPrima BioMed Ltd (PBMD) Under Analyst Spotlight - UK Market News (NASDAQ:PBMD)
www.ukmarketnews.co.uk - January 5 at 11:52 PM
News IconPrima BioMed Enters New Material Transfer Agreement With ... - Yahoo Sports (NASDAQ:PBMD)
sports.yahoo.com - January 5 at 6:03 AM
finance.yahoo.com logoPrima Announces New Product Candidate IMP761 -- A LAG-3 Agonist Antibody (NASDAQ:PBMD)
finance.yahoo.com - January 2 at 6:56 PM
marketexclusive.com logoAnalyst Activity – Maxim Group Reiterates Buy on Prima BioMed Ltd (NASDAQ:PBMD) - Market Exclusive (NASDAQ:PBMD)
marketexclusive.com - December 31 at 6:52 PM
News IconTim Cook plans to open iPhone factory in Bengaluru from April 2017 (NASDAQ:PBMD)
vouxmagazine.com - December 31 at 12:30 AM
News IconGolden Globes confirm first list of presenters (NASDAQ:PBMD)
viveremilano.biz - December 31 at 12:30 AM
News IconNext Weeks Broker Price Targets For Prima BioMed Ltd (PBMD) (NASDAQ:PBMD)
larampadinapoli.com - December 31 at 12:30 AM
News IconPrima BioMed Ltd (PBMD) Given Buy Rating at Maxim Group (NASDAQ:PBMD)
perspectivabetica.com - December 31 at 12:30 AM
marketexclusive.com logoAnalyst Activity – Maxim Group Reiterates Buy on Prima BioMed Ltd (NASDAQ:PBMD) (NASDAQ:PBMD)
marketexclusive.com - December 31 at 12:30 AM
News IconStocks for Your Case: Prima Biomed Ltd. (NASDAQ:PBMD), American Eagle Outfitters, Inc. (NYSE:AEO) - The Newburgh Press (NASDAQ:PBMD)
newburghpress.com - December 30 at 7:30 PM
marketexclusive.com logoHome Stocks Analyst Ratings Analyst Activity – Maxim Group Reiterates Buy on Prima BioMed Ltd (NASDAQ:PBMD) - Market Exclusive (NASDAQ:PBMD)
marketexclusive.com - December 30 at 7:30 PM
zacks.com logoPrima (PBMD) Reports Favorable Initial Melanoma Study Data (NASDAQ:PBMD)
www.zacks.com - December 30 at 9:13 AM
finance.yahoo.com logo6:04 am Prima Biomed announced first clinical data from combination of IMP321 with ANTI-PD1; Database Safety Monitoring Board confirmed that IMP321 is safe and well tolerated (NASDAQ:PBMD)
finance.yahoo.com - December 30 at 9:13 AM
nasdaq.com logoMid-Day Market Update: Prima BioMed Climbs Following Positive IMP321 Data; Interpace Diagnostics Shares Slide (NASDAQ:PBMD)
www.nasdaq.com - December 30 at 12:05 AM
rttnews.com logoINNL Bleeds Over Dashed Hopes, CRBP To Report Data In Q1, FDA Snubs CEMP (NASDAQ:PBMD)
www.rttnews.com - December 30 at 12:05 AM
publicnow.com logoPrima BioMed announces First Clinical Data from Combination of IMP321 with ANTI-PD1 (NASDAQ:PBMD)
us.rd.yahoo.com - December 29 at 9:14 AM
News IconIs the Needle Ready to Move for Prima Biomed Ltd. (NASDAQ:PBMD) - Prospect Journal (NASDAQ:PBMD)
prospectjournal.com - December 28 at 9:49 AM
News IconActive Concerns Wondering Movers: Petroleo Brasileiro S.A. ... - Street Wise Report (press release) (blog) (NASDAQ:PBMD)
streetwisereport.com - December 23 at 7:16 PM
baystreet.ca logoTop Trending Stocks To Watch On Thursday (NASDAQ:PBMD)
ir.baystreet.ca - December 22 at 7:27 PM
investornewswire.com logoPrima BioMed Ltd (NASDAQ:PBMD) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:PBMD)
www.investornewswire.com - December 22 at 12:59 AM
News IconCan This Stock Gain Any Traction: Prima Biomed Ltd. (NASDAQ:PBMD) - Prospect Journal (NASDAQ:PBMD)
prospectjournal.com - December 22 at 12:59 AM
streetinsider.com logoPrima BioMed (PBMD) Announces Interim Data From IMP321 ... - StreetInsider.com (NASDAQ:PBMD)
www.streetinsider.com - December 22 at 12:59 AM
streetinsider.com logoPrima BioMed (PBMD) Announces Interim Data From IMP321 AIPAC Trial (NASDAQ:PBMD)
www.streetinsider.com - December 21 at 7:58 PM
us.rd.yahoo.com logo4:36 pm Prima Biomed announces interim data from the AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer; initial data confirms previous trial results showing IMP321 is safe and well tolerated (NASDAQ:PBMD)
us.rd.yahoo.com - December 21 at 7:58 PM
finance.yahoo.com logoPrima Biomed trial results positive (NASDAQ:PBMD)
au.finance.yahoo.com - December 21 at 7:58 PM
publicnow.com logoPrima BioMed Announces Data from IMP321 AIPAC Clinical Trial in Breast Cancer (NASDAQ:PBMD)
www.publicnow.com - December 21 at 7:58 PM
News IconEtching Out Gains Pre-Bell, Shares Pick Up Momentum: Prima Biomed Ltd. (NASDAQ:PBMD) - Prospect Journal (NASDAQ:PBMD)
prospectjournal.com - December 20 at 1:34 PM

Social

What is Prima BioMed Ltd's stock symbol?

Prima BioMed Ltd trades on the NASDAQ under the ticker symbol "PBMD."

Where is Prima BioMed Ltd's stock going? Where will Prima BioMed Ltd's stock price be in 2017?

4 analysts have issued twelve-month price targets for Prima BioMed Ltd's stock. Their predictions range from $6.00 to $7.50. On average, they expect Prima BioMed Ltd's share price to reach $6.63 in the next twelve months.

What are analysts saying about Prima BioMed Ltd stock?

Here are some recent quotes from research analysts about Prima BioMed Ltd stock:

  • According to Zacks Investment Research, "Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company's key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. " (1/27/2017)

  • FBR & Co analysts commented, "On January 20, Prima BioMed announced the first patient dosing in the enlarged randomized portion of the AIPAC Phase IIb study with IMP321 in metastatic breast cancer (mBC). We think clinical progress with IMP321 is significantly under- appreciated, as the latest news is the seventh announcement since late November 2016. We also point to multiple value inflection points in 2017 that we think could be positive catalysts. PBMD also continues to make progress with its Phase I trial in melanoma (TACTI-mel), testing IMP321 plus a PD-1 blocking antibody (Keytruda), a hot immunotherapeutic anti-cancer strategy, and recently added a LAG-3 agonist antibody, IMP761, to its internal pipeline." (1/24/2017)

How do I buy Prima BioMed Ltd stock?

Shares of Prima BioMed Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Prima BioMed Ltd stock cost?

One share of Prima BioMed Ltd stock can currently be purchased for approximately $2.47.

Prima BioMed Ltd (NASDAQ:PBMD) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Prima BioMed Ltd (NASDAQ:PBMD)

Earnings History Chart

Earnings by Quarter for Prima BioMed Ltd (NASDAQ:PBMD)

Dividend History Chart

Dividend Payments by Quarter for Prima BioMed Ltd (NASDAQ:PBMD)

Last Updated on 2/19/2017 by MarketBeat.com Staff